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Ischemia-induced angiogenesis is critical for tissue repair, but aberrant neovascularization in the retina
causes severe sight impairment. Nitric oxide (NO) has been implicated in neovascular eye disease
because of its pro-angiogenic properties in the retina. Nitric oxide production is inhibited endogenously
by asymmetric dimethylarginines (ADMA and L-NMMA) which are metabolized by dimethylarginine
dimethylaminohydrolase (DDAH) 1 and 2. The aim of this study was to determine the roles of DDAH1,
DDAH2, ADMA and L-NMMA in retinal ischemia-induced angiogenesis. First, DDAH1, DDAH2, ADMA and
L-NMMA levels were determined in adult C57BL/6J mice. The results obtained revealed that DDAH1 was
twofold increased in the retina compared to the brain and the choroid. DDAH2 expression was
approximately 150 fold greater in retinal and 70 fold greater in choroidal tissue compared to brain tissue
suggesting an important tissue-speciﬁc role for DDAH2 in the retina and choroid. ADMA and L-NMMA
levels were similar in the retina and choroid under physiological conditions. Next, characterization of
DDAH1þ/ and DDAH2/ deﬁcient mice by in vivo ﬂuorescein angiography, immunohistochemistry and
electroretinography revealed normal neurovascular function compared with wildtype control mice.
Finally, DDAH1þ/ and DDAH2/ deﬁcient mice were studied in the oxygen-induced retinopathy (OIR)
model, a model used to emulate retinal ischemia and neovascularization, and VEGF and ADMA levels
were quantiﬁed by ELISA and liquid chromatography tandem mass spectrometry. In the OIR model,
DDAH1þ/ exhibited a similar phenotype compared to wildtype controls. DDAH2 deﬁciency, in contrast,
resulted in elevated retinal ADMA which was associated with attenuated aberrant angiogenesis and
improved vascular regeneration in a VEGF independent manner. Taken together this study suggests, that
in retinal ischemia, DDAH2 deﬁciency elevates ADMA, promotes vascular regeneration and protects
against aberrant angiogenesis. Therapeutic inhibition of DDAH2 may therefore offer a potential thera-
peutic strategy to protect sight by promoting retinal vascular regeneration and preventing pathological
angiogenesis.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).L Institute of Ophthalmology,
ge).
, College of Veterinary Medi-
oore Drive, Raleigh, NC, USA.
, F. Hoffmann-La Roche Ltd,
r Ltd. This is an open access article1. Introduction
Adaptive tissue responses to ischemia promote blood ﬂow and
angiogenesis that are critical for normal development, tissue repair
and regeneration. In the mature retina, however, ischemia-induced
angiogenesis is typically misdirected into the vitreous gel where it
not only fails to redress retinal ischemia but also exacerbates
impairment of sight with haemorrhage into the vitreous gel and
tractional retinal detachment (Foster and Resnikoff, 2005).under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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molecular mediators, cellular interactions and extracellular matrix
modulation, and is the target of novel therapeutic approaches (for a
review see (De Oliveira Dias et al., 2011)). Local therapeutic inhi-
bition of vascular endothelial growth factor (VEGF) attenuates
pathological neovascularization (Avery et al., 2006) but this strat-
egy fails to promote effective revascularization of ischemic retina.
The ubiquitous biological messenger nitric oxide (NO) promotes
vascular dilatation by cGMP-induced smooth muscle relaxation
(Archer et al., 1994). In the eye, NO promotes angiogenesis in
experimental models of pathological neovascularization (Ando
et al., 2002) and is elevated in the vitreous of human subjects
with proliferative diabetic retinopathy (Hernandez et al., 2002). NO
synthesis from L-arginine is catalyzed by 3 isoforms of nitric oxide
synthase (NOS) with distinct tissue distributions: endothelial NOS
(eNOS), neuronal NOS (nNOS) and inducible NOS (iNOS). Asym-
metric dimethylarginine (ADMA) and other asymmetrically meth-
ylated arginine analogs (L-NMMA) are key regulators of NO
synthesis as they competitively inhibit the binding of L-arginine for
the active site of NOS (Vallance et al., 1992). Asymmetric methyl-
arginines are endogenously produced on degradation of proteins
containing asymmetrically methylated L-arginine residues, and are
metabolized to citrulline and dimethylamine by dimethylarginine
dimethylaminohydrolases-1 (DDAH1) and -2 (DDAH2) (Fig. 1)
(Leiper et al., 1999; Ogawa et al., 1987). These two DDAH isoforms
have distinct tissue distributions (Leiper et al., 1999) suggesting
isoform-speciﬁc regulation of NOS. DDAH1 is predominantly found
in tissues that express nNOSwhereas DDAH2 is found in high levels
in tissues expressing eNOS, which has a role in promoting angio-
genesis in the retina (Fukumura et al., 2001; Brooks et al., 2001).
Here we show that in retinal ischemia, DDAH2 deﬁciency ele-
vates ADMA, promotes retinal vascular regeneration and protects
against aberrant neovascularization.2. Material and methods
2.1. Generation and identiﬁcation of DDAH knockout mice
DDAH1þ/ knockout mice were generated as previously
described (Leiper et al., 2007). Since global homozygous deletion of
DDAH1 is lethal in utero all experiments were performed onFig. 1. Regulation of Nitric Oxide synthesis by Methylarginines (ADMA and L-
NMMA). L-arginine is the substrate for nitric oxide synthase (NOS) enzymes. Arginine
residues in proteins are methylated by protein arginine methyl transferases. Following
proteolysis of arginine-methylated proteins, methylarginines (ADMA and L-NMMA)
accumulate in the cytosol where they can inhibit NOS activity by competing with
arginine at the NOS active site. Inhibitory methylarginines are metabolized by the
action of dimethylarginine dimethylaminohydrolase (DDAH1 and DDAH2).DDAH1þ/ mice (Leiper et al., 2007). Heterozygous DDAH2þ/ ge-
netic knockout mice were obtained from the Texas Institute for
Genomic Medicine (http://www.tigm.org/) and bred to generate
homozygous DDAH2/, heterozygous DDAH2þ/ and wildtype
DDAH2þ/þ mice. All animals were managed in accordance with the
guidelines of the Association for Research in Vision and Ophthal-
mology. In all experiments, weight-matched wildtype littermates
were compared to circumvent inter-litter variability.
2.2. Oxygen-induced retinopathy mouse model (OIR)
Nursing dams and their pups were kept at 75 ± 3% O2 in an
oxygen supply chamber from postnatal day (p) 7 to p12, returned to
room air on p12 and culled at p12 or p17 as described elsewhere
(Lange et al., 2009). The area of ischemia and neovascularization
was studied as previously described (Wang et al., 2013).
2.3. Laser-induced choroidal neovascularization (CNV)
Laser-CNV induction and in vivo fundus ﬂuorescein angiography
7 and 14 days after laser was performed as previously described
(Wang et al., 2013).
2.4. Electroretinography
Standard photopic and scotopic Ganzfeld ERG’s were recorded
bilaterally in dark-adapted mice using the electrophysiological
system Espion 2000 (Espion E2, Diagnosys LLC, Cambridge, UK) as
previously described (Mowat et al., 2012).
2.5. Chemical analysis
Methylarginines were quantiﬁed using liquid chromatography
tandem mass spectrometry as previously described (Caplin and
Leiper, 2012). VEGF protein levels were determined using a
commercially available ELISA kit (mouse VEGF DuoSet ELISA kit,
R&D, Systems Europe, Abingdon, UK) and were corrected for total
protein levels. Western blotting protein analysis was performed for
DDAH1 and DDAH2 in brain, retinal and choroidal tissue as previ-
ously described (Mowat et al., 2010). Mouse beta actin was used as
an internal loading control. Since DDAH and beta actin have similar
sizes, beta actin was used after stripping and reprobing of the blot.
Primary antibodies for DDAH1 (1:1000) and 2 (1:2500) were raised
in goats against peptide sequences which are conserved across rats,
humans, and mice as previously described (Wojciak-Stothard et al.,
2007).
2.6. Immunohistochemistry
Eyes of anaesthetized animals were ﬁxed by intracardiac
perfusion using 1% paraformaldehyde. Haematoxylin and eosin
staining histology and immunohistochemistry were performed as
previously described (Lange et al., 2012). DDAH immunohisto-
chemistry was performed using polyclonal rabbit anti-DDAH I
(1:2000) and polyclonal rabbit anti-DDAH II antibodies (1:2000,
generated in house) as previously described (Gray et al., 2010).
2.7. Statistical analysis
Data from knockout animals were normalized to littermate
controls. Data were compared using the non-parametric Mann-
Whitney U test. Mean variables of more than two groups were
compared by ANOVA with Bonferroni corrections for multiple
comparisons. P-values less than 0.05 were considered statistically
signiﬁcant.
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3.1. Methylarginines and DDAH isoforms are differentially
distributed in the murine eye
To investigate the distribution of ADMA, L-NMMA and their
catabolizing enzyme DDAH1 and DDAH2 in the retina and choroid/
RPE of normal adult C57BL/6J mice we performed immunohisto-
chemistry, Western blotting and liquid chromatography tandem
mass spectrometry. Immunohistochemistry revealed that DDAH1
and DDAH2 are expressed in the ganglion cell layer, the inner nu-
clear layer and the photoreceptor layer. In addition DDAH2 but not
DDAH1 was expressed in the choroidal vasculature (Fig. 2AeC).
Using Western blot analysis on wildtype samples we found aFig. 2. DDAH1 and DDAH2 expression in the retina. A,B) DDAH1 and DDAH2 immunohis
DDAH2 protein levels in the brain, retina and choroid/RPE in adult C57BL/6J mice and rep
centration in the retina and choroid/RPE in adult C57BL/6J mice (n ¼ 5 animals per grou
OPL ¼ outer plexiform layer; ONL ¼ outer nuclear layer; Cho ¼ choroid; RPE ¼ retinal pigmtwofold increase of DDAH1 expression in the retina compared to
the brain and the choroid. DDAH2 expression in contrast was
approximately 150 fold greater in retinal and 70 fold greater in
choroidal tissue compared to brain tissue suggesting an important
tissue-speciﬁc role for DDAH2 in the retina and choroid (Fig. 2D and
E). ADMA concentrations were comparable in both retinal and
choroidal tissue. L-NMMA concentration was also similar in the
retina and choroid but at substantially higher concentrations than
ADMA (Fig. 2F and G).3.2. Heterozygous loss of DDAH1 and homozygous loss of DDAH2
are not essential for neurovascular function
We next explored the role of DDAH1 and DDAH2 in normaltochemistry in adult C57BL/6J mice. C) No primary antibody control. D,E) DDAH1 and
resentative Western blots (n ¼ 5 animals per group). F,G) ADMA and L-NMMA con-
p). GCL ¼ ganglion cell layer; IPL ¼ inner plexiform layer; INL inner nuclear layer;
ent epithelium. Bars represent mean (±SEM).
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immunohistochemistry and electroretinography. DDAH1þ/,
DDAH2þ/ and DDAH2/ knockout mice demonstrated a normal
vascular phenotype and normal neuroretinal functioning when
compared to littermate controls (Fig. 3E and F, S1A and B).3.3. Loss of DDAH2 reduces pathogenic retinal ischemia and
neovascularization
Having established that heterozygous loss of DDAH1 or homo-
zygous loss of DDAH2 has no effect on the adult retinal vasculature,
we next investigated the role of DDAH1 and DDAH2 in murine
oxygen-induced retinopathy (OIR), a model of retinal ischemia-
induced neovascularization. In OIR, exposure of young mice to
hyperoxia (75% inhaled oxygen) from postnatal day 7 (p7) results in
ablation of immature retinal vasculature. On return to room air at
p12 the ischemic retina becomes hypoxic, leading to upregulation
of adaptive angiogenic processes. Neovascularization, however,
fails to revascularize ischemic retina appropriately and instead is
misdirected into the vitreous, in a pattern that recapitulates key
features of proliferative diabetic retinopathy. Heterozygous DDAH1
knockout mice demonstrated a similar oxygen-induced retinalFig. 3. DDAH2 deﬁciency does not alter retinal neurovascular morphology and functio
stained retinal ﬂatmounts and (D) cryosections of control (ﬁrst column), DDAH2þ/ (secon
per group). E) H&E histology reveals a normal retinal layering and thickness in control, DD
electroretinogram recordings and quantiﬁcation of the a- and b-wave amplitude at 1 Cds/m2
(n ¼ 6 animals per group); GCL ¼ ganglion cell layer; IPL ¼ inner plexiform layer; INL inner
RPE ¼ retinal pigment epithelium. Bars represent mean (±SEM).vascular ablation at p12 and a similar area of retinal neo-
vascularization at p17 compared with littermate controls (Fig. 4G
and H). DDAH2þ/ knockout mice were similarly susceptible to
oxygen-induced retinal vascular ablation as their littermate
(DDAH2þ/þ) controls. At p17 however, heterozygous DDAH2þ/
knockout mice developed greater revascularization of the area of
retinal vascular ablation, resulting in less extensive ischemia, and
less extensive aberrant pre-retinal neovascularization. Having
identiﬁed an effect of DDAH2 haploinsufﬁciency we then deter-
mined that in DDAH2 null (DDAH2/) mice the magnitude of this
response to OIR was greater still (Fig. 4AeI). These data indicate
that dose dependent reduction of DDAH2 promotes appropriate
revascularization and reduces aberrant angiogenesis in retinal
ischemia.3.4. DDAH2 deﬁciency does not alter retinal VEGF levels in the OIR
model
Since DDAH2 can induce expression of vascular endothelial
growth factor (VEGF), which is well recognized for its pro-
angiogenic role in OIR, we next investigated retinal VEGF protein
levels in DDAH2-deﬁcient mice during OIR. The concentration ofn. A) Representative infrared fundus images, (B) ﬂuorescein angiography, (C) vessel-
d column) and DDAH2/ littermates (right column) at one month of age (n ¼ 3e4
AH2þ/ and DDAH2/ knockout mice (n ¼ 3e4 per group). F) Representative scotopic
intensity in adult DDAH1þ/, DDAH2þ/ DDAH2/ and their representative littermates
nuclear layer; OPL ¼ outer plexiform layer; ONL ¼ outer nuclear layer; Cho ¼ choroid;
Fig. 4. DDAH2-deﬁciency increases ADMA levels in retinal ischemia, promotes revascularization and attenuates aberrant neovascularization. AeF) Representative vessel-
stained retinal ﬂatmounts of DDAH2þ/þ (control), DDAH2þ/ and DDAH2/ littermates at p12 (AeC) and p17 (DeF) in oxygen-induced retinopathy (OIR). The ischemic area is
outlined in white; the area of aberrant neovascularization is highlighted in yellow. G,H)Mean area of neovascularization (G) and ischemic fraction (H) in DDAH1þ/ (n ¼ 6), DDAH2/
þ (n ¼ 21) DDAH2/ (n ¼ 10) and their representative wildtype littermate controls (n ¼ 15, n ¼ 6) at P17 after OIR induction (data is presented as percentage of total retinal area
relative to wildtype littermate controls). I) Timecourse of mean ischemic fraction of total retinal area in DDAH2þ/þ, DDAH2þ/ and DDAH2/ littermates at p12 and p17 in oxygen
induced retinopathy (range n ¼ 5e8 per group). JeL) Mean retinal VEGF protein (J), ADMA (K) and L-NMMA (L) levels in DDAH2þ/þ controls, DDAH2þ/ and DDAH2/ littermates
(range n ¼ 5e8 per group) at p17 under normoxic condition and after OIR induction (data is presented relative to normoxic wildtype littermate controls). Bars represent mean
(±SEM). NV ¼ neovascularization. **** ¼ p < 0.0001, *** ¼ p < 0.001, ** ¼ p < 0.01 (ANOVA with the Bonferroni correction for multiple signiﬁcance tests).
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hypoxic phase of OIR. However, the concentration of VEGF was
unaffected by DDAH2 deﬁciency (Fig. 4J) indicating that the
observed attenuated neovascular response is independent of local
VEGF.
3.5. Retinal ADMA is increased by DDAH2-deﬁciency in retinal
ischemia
Next, we determined the impact of DDAH2 on retinal ADMA and
L-NMMA in OIR by liquid chromatography tandem mass spec-
trometry. During the hypoxic phase of OIR at p17, retinal ADMAwas
signiﬁcantly increased in DDAH2/ mice (Fig. 4K) suggesting that
increased ADMA attenuates the development of retinal neo-
vascularization. Although L-NMMA is present in the normal retina
at higher levels than ADMA, we identiﬁed no measurable impact of
OIR or DDAH2-deﬁciency on local L-NMMA (Fig. 4L).
3.6. DDAH2 does not inﬂuence pathogenic choroidal
neovascularization
To investigate the role of DDAH1 and DDAH2 in angiogenesis in
choroidal neovascularization (CNV), a feature of age-related mac-
ular degeneration, we measured the extent of CNV induced by
laser-rupture of Bruch’s membrane in heterozygous DDAH1 and
homozygous DDAH2 deﬁcient mice. We identiﬁed no signiﬁcant
difference in the extent of CNV in DDAH1þ/, DDAH2þ/ and
DDAH2/ compared with littermate controls (SFig. 1 and 2) sug-
gesting that heterozygous loss of DDAH1 and loss of DDAH2 do not
affect the development of CNV.
4. Discussion
Therapeutic strategies that promote new vessel growth into the
ischemic retina and away from the vitreous body would be
extremely beneﬁcial for patients with ischemic retinopathy, such as
proliferative diabetic retinopathy and retinal vein occlusion. In this
study we aimed to explore the role of ADMA and L-NMMA and its
catabolizing enzyme DDAH1 and DDAH2, which are potent regu-
lators of NO synthesis, on vascular regeneration and pathological
neovascularization. To do this we investigated the expression of
ADMA and L-NMMA in the ischemic murine retina and character-
ized DDAH1 and DDAH2 knockout mice in health and in an
established model for retinal ischemia and neovascularization.
We found that DDAH1 and DDAH2 are expressed to a similar
extent in the murine retina while DDAH2 is the predominant iso-
form found in the choroid and RPE. Interestingly, DDAH2 expres-
sion is approximately 1000fold greater in the retina than in the
brain indicating an important tissue-speciﬁc role for DDAH2 in the
retina.
To determine the effect of reduced DDAH1 and absent DDAH2
activity on retinal ischemia and neovascularizationwe investigated
DDAH1þ/ and DDAH2/ deﬁcient mice in two establishedmodels
of ocular neovascularization. We could previously show that
DDAH1þ/ mice exhibit reduced DDAH1 protein expression and
elevated circulating and tissue ADMA concentrations (Leiper et al.,
2007) which was associated with attenuated hemodynamic con-
sequences in endotoxemia (Nandi et al., 2012). However, in the OIR
and CNV mouse models heterozygous loss of DDAH1 had no effect
on retinal ischemia or the formation of ocular neovascularization.
This ﬁnding is in contrast to the literature which reports on a
proangiogenic role of DDAH1. Overexpression of DDAH1 in trans-
genic mice is associated with enhanced angiogenesis in a murine
model of hindlimb ischemia (Jacobi et al., 2005) and with
augmented endothelial regeneration after femoral artery injury.(Konishi et al., 2007). Conversly, homozygous loss and endothelial
cell speciﬁc knockout of DDAH1 is associated with reduced angio-
genesis in vitro (Zhang et al., 2011; Hu et al., 2009). Such disparate
ﬁndings might be explained by the different mouse models used in
the studies and by the omission of homozygous DDAH1/ deﬁ-
cient mice from this study as they die in utero (Leiper et al., 2007).
Future studies using viable DDAH1/ or cell-speciﬁc conditional
knockout mice are warranted to determine the role of DDAH1 in
retinal ischemia and neovascularization with greater conﬁdence.
We could recently demonstrate that DDAH2 is an important
isoform for ADMA degradation in myocardial and renal tissue
(Lambden et al., 2015). To assess the role of DDAH2 on ADMA levels,
retinal ischemia and neovascularization we investigated DDAH2
deﬁcient mice in health and in the OIRmouse model. Under normal
conditions DDAH2 is predominately expressed in the ganglion cell
layer, photoreceptor layers and to a lesser extent in the inner nu-
clear layer. DDAH2 deﬁciency caused no abnormality of retinal
development or retinal vasculature in adult mice on fundus imag-
ing, in vivo ﬂuorescein angiography, immunohistochemistry or
electroretinography indicating that DDAH2 does not affect normal
neuroretinal development or function. These ﬁndings are consis-
tent with previous reports demonstrating that eNOS knockout mice
exhibit normal retinal vascular development and retinal function
(Al-Shabrawey et al., 2003). Under ischemic conditions, however,
DDAH2 deﬁciency was associated with increased ADMA levels,
reduced aberrant angiogenesis and improved vascular regenera-
tion. These data indicate that DDAH2 deﬁciency and increased
ADMA promotes appropriate revascularization and reduces aber-
rant angiogenesis in retinal ischemiamost likely via an inhibition of
NO synthase. These data are consistent with previous studies
demonstrating that deﬁciency of endothelial- or inducible-NOS
suppresses retinal neovascularization and improves vascular
repair in the OIR model (Sennlaub et al., 2001; Brooks et al., 2001).
iNOS-deﬁcient mice develop a substantial reduction of the area of
ischemia by about 70% and a reduction of preretinal neo-
vascularization by about 85% at p17 (Sennlaub et al., 2001). eNOS-
deﬁcient mice exhibit a 46% reduction of the area of retinal
ischemia and a reduction of retinal neovascularization by about 66%
(Brooks et al., 2001) similar to our own ﬁndings in DDAH2-deﬁcient
mice. In addition to their roles in the regulation of NO production,
DDAH enzymes are also involved in NOS-independent pathways.
Since DDAH2 can induce expression of vascular endothelial growth
factor (VEGF) in cultured endothelial cell (Hasegawa et al., 2006),
which is well recognized for its pro-angiogenic role in OIR (Aiello
et al., 1995), we investigated retinal VEGF protein levels in
DDAH2-deﬁcient mice during OIR. The concentration of VEGF
protein was signiﬁcantly raised in the retina during the hypoxic
phase of OIR, a ﬁnding that is consistent with previous reports
(Pierce et al., 1996). We could recently show that VEGF is expressed
in the ganglion cell layer, the inner nuclear layer and the retinal
pigmented epithelium upon OIR induction (Liyanage et al., 2016).
However, the concentration of VEGF was unaffected by DDAH2
deﬁciency indicating that DDAH2 deﬁciency does not affect VEGF
expression in these cell layers. Taken together the data suggests
that locally increased levels of the NOS inhibitor ADMA promotes
retinal vascular regeneration and attenuates aberrant neo-
vascularization independently of local VEGF concentration. This
hypothesis is consistent with previous studies demonstrating that
deﬁciency of endothelial- or inducible-NOS suppresses retinal
neovascularization and improves vascular regeneration in retinal
ischemia independent of VEGF (Ando et al., 2002; Brooks et al.,
2001; Sennlaub et al., 2001).
There is ongoing controversy concerning the distribution and
functional contribution of DDAH1 and DDAH2 to the degradation of
ADMA. Using DDAH1 knockout mice Hu et al. convincingly
C. Lange et al. / Experimental Eye Research 147 (2016) 148e155154demonstrated that DDAH1 is responsible for the majority of
enzyme activity for metabolizing ADMA in the kidney, brain, lung
and plasma (Hu et al., 2011). Selective DDAH2 gene silencing by
siRNA was shown to have no effect on ADMA content in cultured
bovine aortic endothelial cells or on serum ADMA in unchallenged
rats (Wang et al., 2007; Hu et al., 2011) suggesting that DDAH2
might not metabolize ADMA in vivo (Pope et al., 2009). These
studies on DDAH2, however, may have been limited by gene
silencing efﬁcacy and by the fact that ADMA was measured in
endothelial cells in vitro and in the blood but not in tissues. Using
DDAH2 knockout mice we could recently demonstrate that DDAH2
has an important role in degrading ADMA in myocardial and renal
tissue (Lambden et al., 2015) which is in line with the ﬁnding of
increased retinal ADMA in challenged DDAH2 knockout mice, as
observed in this study.
Moreover, DDAH2 gene silencing studies indicate that DDAH2
regulates tissue ADMA levels and NO bioavailabilty in isolated
mesenteric resistance vessels (Wang et al., 2007) and human ge-
netic studies demonstrate that polymorphisms in the DDAH2 gene
are associated with altered plasma ADMA levels (Abhary et al.,
2010). Taken together these studies indicate that DDAH2 does
indeed contribute to ADMA regulation in particular in highly vas-
cularized tissues such as the retina.
5. Conclusions
In summary, our results indicate that DDAH2 prevents ADMA
upregulation in retinal ischemia, impairing retinal vascular regen-
eration and promoting aberrant neovascularization. Deﬁciency of
DDAH2 does not affect normal neuroretinal development or func-
tion but, in the context of ischemia, strongly promotes vascular
regeneration and protects against pathological neovascularization.
This mechanism is gene dose-dependent, tissue-selective and in-
dependent of VEGF. Therapeutic intervention to increase ADMA, for
example by small molecules inhibition of DDAH2 (Leiper and
Nandi, 2011), may offer the means to promote vascular regenera-
tion and prevent retinal neovascularization in common conditions
associated with retinal ischemia.
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